MIRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MIRA Pharmaceuticals Inc is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals or analyst ratings to support a buy decision. Holding off for now is recommended.
The MACD is positive but contracting, RSI is neutral at 44.358, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 1.064, with resistance levels at 1.121 and 1.157, and support levels at 1.007 and 0.971.
NULL identified. No recent news, no significant insider or hedge fund activity, and no recent congress trading data.
Weak financial performance with no revenue growth, negative net income, and no clear valuation data. Lack of significant trading trends or news-driven catalysts.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$5,983,321 (up 149.34% YoY), and an EPS of -0.15 (up 7.14% YoY). Gross margin remained at 0%. Overall, financials are weak with no clear growth trajectory.
No analyst ratings or price target changes available.
